Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | BGB-C354 |
| Trade Name | |
| Synonyms | BGB C354|BGBC354 |
| Drug Descriptions |
BGB-C354 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting CD276 (B7-H3) linked to a topoisomerase I inhibitor, which potentially induces cytotoxicity in CD276 (B7-H3)-expressing tumor cells and antitumor activity (Cancer Res (2025) 85 (8_Supplement_1): 5731). |
| DrugClasses | CD276 Antibody 21 |
| CAS Registry Number | NA |
| NCIT ID | C210858 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| BGB-C354 | BGB-C354 | 0 | 1 |
| BGB-C354 + Tislelizumab | BGB-C354 Tislelizumab | 0 | 1 |